Eighty dollars a share is certainly a fair price for this business that we suspect is not nearly as damaged as the media coverage would suggest. It becomes increasingly difficult for J&J to follow Boston's lead on price. |
It implies there is room for a counter offer. |
It's a slam-dunk for Boston Scientific, and I think there are implications for the rest of the industry. |
Strong leadership and better communication would likely turn it around within 18 to 24 months. |
This is standard stuff, and the numbers don't blow me away. I certainly expect there to be dozens, if not hundreds, of patients who come forward. It's premature to try to predict the ultimate disposition of the cases. |
We expect the company to be a cardiovascular powerhouse, worth more together than on a stand-alone basis. |